Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation - a retrospective study.
Gentamicin
Neonate
Pharmacokinetics
Traditional dosing, extended-interval dosing, Monte Carlo simulation
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
06 09 2019
06 09 2019
Historique:
received:
16
04
2019
accepted:
19
08
2019
entrez:
8
9
2019
pubmed:
8
9
2019
medline:
15
12
2020
Statut:
epublish
Résumé
Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration attainment for conventional and extended-interval dosing (EID) regimens. Patient demographics and steady-state gentamicin concentration data were retrospectively collected for 60 neonates with no renal impairment admitted to a level III neonatal intensive care unit. Mean pharmacokinetics were calculated and multiple linear regression was performed to determine significant covariates of clearance (L/h) and volume of distribution (L). Classification and regression tree (CART) analysis identified breakpoints for significant covariates. Monte Carlo Simulation (MCS) was used to determine optimal dosing recommendations for each CART-identified sub-group. Gentamicin clearance and volume of distribution were significantly associated with weight at gentamicin initiation. CART-identified breakpoints for weight at gentamicin initiation were: ≤ 850 g, 851-1200 g, and > 1200 g. MCS identified that a conventional dose of gentamicin 3.5 mg/kg given every 48 h or an EID of 8-9 mg/kg administered every 72 h in neonates weighing ≤ 850 g, and every 24 and 48 h, respectively, in neonates weighing 851-1200 g, provided the best probability of attaining conventional (peak: 5-10 mg/L and trough: ≤ 2 mg/L) and EID targets (peak:12-20 mg/L, trough:≤ 0.5 mg/L). Insufficient sample size in the > 1200 g neonatal group precluded further investigation of this weight category. This study provides initial gentamicin dosing recommendations that optimize target attainment for conventional and EID regimens in neonates weighing ≤ 1200 g. Prospective validation and empiric dose optimization for neonates > 1200 g is needed.
Sections du résumé
BACKGROUND
Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration attainment for conventional and extended-interval dosing (EID) regimens.
METHODS
Patient demographics and steady-state gentamicin concentration data were retrospectively collected for 60 neonates with no renal impairment admitted to a level III neonatal intensive care unit. Mean pharmacokinetics were calculated and multiple linear regression was performed to determine significant covariates of clearance (L/h) and volume of distribution (L). Classification and regression tree (CART) analysis identified breakpoints for significant covariates. Monte Carlo Simulation (MCS) was used to determine optimal dosing recommendations for each CART-identified sub-group.
RESULTS
Gentamicin clearance and volume of distribution were significantly associated with weight at gentamicin initiation. CART-identified breakpoints for weight at gentamicin initiation were: ≤ 850 g, 851-1200 g, and > 1200 g. MCS identified that a conventional dose of gentamicin 3.5 mg/kg given every 48 h or an EID of 8-9 mg/kg administered every 72 h in neonates weighing ≤ 850 g, and every 24 and 48 h, respectively, in neonates weighing 851-1200 g, provided the best probability of attaining conventional (peak: 5-10 mg/L and trough: ≤ 2 mg/L) and EID targets (peak:12-20 mg/L, trough:≤ 0.5 mg/L). Insufficient sample size in the > 1200 g neonatal group precluded further investigation of this weight category.
CONCLUSIONS
This study provides initial gentamicin dosing recommendations that optimize target attainment for conventional and EID regimens in neonates weighing ≤ 1200 g. Prospective validation and empiric dose optimization for neonates > 1200 g is needed.
Identifiants
pubmed: 31492162
doi: 10.1186/s12887-019-1676-3
pii: 10.1186/s12887-019-1676-3
pmc: PMC6729057
doi:
Substances chimiques
Anti-Bacterial Agents
0
Gentamicins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318Références
Clin Pharmacokinet. 1988 May;14(5):261-86
pubmed: 3293867
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7
pubmed: 23587776
Clin Infect Dis. 1997 May;24(5):786-95
pubmed: 9142771
J Pediatr. 2008 Oct;153(4):530-4
pubmed: 18589452
Clin Pharmacokinet. 2009;48(2):71-88
pubmed: 19271781
Br J Clin Pharmacol. 2014 Nov;78(5):1090-101
pubmed: 24938850
Kidney Int. 2005 Aug;68(2):731-40
pubmed: 16014050
Antimicrob Agents Chemother. 1995 Mar;39(3):650-5
pubmed: 7793867
BMJ. 1996 Feb 10;312(7027):338-45
pubmed: 8611830
Cochrane Database Syst Rev. 2016 Dec 06;12:CD005091
pubmed: 27921299
Arch Dis Child Fetal Neonatal Ed. 2005 Jul;90(4):F294-300
pubmed: 15857879
Pediatr Infect Dis J. 2001 Dec;20(12):1169-73
pubmed: 11740327
N Engl J Med. 2002 Jul 25;347(4):240-7
pubmed: 12140299
J Antimicrob Chemother. 2004 Jul;54(1):193-8
pubmed: 15150171
J Antimicrob Chemother. 2009 May;63(5):1043-9
pubmed: 19299469
Clin Infect Dis. 1997 May;24(5):796-809
pubmed: 9142772
Ther Drug Monit. 1999 Oct;21(5):514-9
pubmed: 10519447
J Antimicrob Chemother. 2015 Jul;70(7):2074-7
pubmed: 25766737
Clin Pharmacokinet. 1988 Apr;14(4):189-216
pubmed: 3292100
Pharmacotherapy. 2009 Nov;29(11):1297-305
pubmed: 19857147
J Antimicrob Chemother. 1992 Apr;29(4):427-33
pubmed: 1607331
J Antimicrob Chemother. 1996 Apr;37(4):645-63
pubmed: 8722531
J Perinatol. 2003 Dec;23(8):635-9
pubmed: 14647159
Pediatrics. 2004 Jul;114(1):e111-8
pubmed: 15231982
Acta Paediatr. 2012 Nov;101(11):1134-9
pubmed: 22897142
J Antimicrob Chemother. 2001 Dec;48(6):887-93
pubmed: 11733474
J Infect Dis. 1987 Jan;155(1):93-9
pubmed: 3540140
Can J Hosp Pharm. 2012 Jan;65(1):31-6
pubmed: 22479110
J Antimicrob Chemother. 2006 Aug;58(2):372-9
pubmed: 16782742
Pediatr Infect Dis J. 1995 Jan;14(1):71-2
pubmed: 7715998
Clin Pharmacokinet. 2009;48(4):253-63
pubmed: 19492870
Pediatrics. 1999 Jun;103(6 Pt 1):1228-34
pubmed: 10353934
J Pediatr. 1997 Jul;131(1 Pt 1):76-80
pubmed: 9255195
Pharmacotherapy. 2003 May;23(5):585-91
pubmed: 12741432